AnticoaguLation ONE year after ablation of atrial fibrillation in patients with Atrial Fibrillation (ALONE AF study)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0005142

Enrollment

840

Registered

2020-06-17

Start date

2020-07-28

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Arm1 ??: Anticoagulation group(Apixaban group) apixaban component of drugs: Elxaban tab., Eliquis tab., Apiquis tab., Liquixia tab., Yuhanapixaban tab.. Dose: 2.5mg/5mg Regimen: twice daily Du

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. no recurrence of atrial fibrillation one year after catheter ablation of atrial fibrillation 2. CHA2DS2-VASc score >=1 (male) or >=2 (female) 3. age: 19 to 80 years 4. non-valvular atrial fibrillation 5. those who consent the study. 6. those who can be followed after enrollement

Exclusion criteria

Exclusion criteria: 1. Severe liver or kidney dysfunction 2. Thyroid dysfunction 3. Pregnant or breastfeeding women 4. Malignant tumors that have not been completely cured 5. Severe structural heart disease 6. Predicted survival is less than 12 months 7. Patients who do not understand the content of the study or disagree with it

Design outcomes

Primary

Measure	Time frame
composite outcome including stroke/systemic embolism and major bleeding	—

Secondary

Measure	Time frame
systemic embolism;major bleeding	—

Countries

Korea, Republic of

Contacts

Public ContactHyunsun Baek

Yonsei University Health System, Severance Hospital

cardiocrc13@yuhs.ac+82-2-2228-8528

Outcome results